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Abstract: The role of interleukin-11 (IL-11) was
evaluated in the IgG immune complex model of
acute lung injury in rats. IL-11 mRNA and protein
were both up-regulated during the course of this
inflammatory response. Exogenously administered
IL-11 substantially reduced, in a dose-dependent
manner, the intrapulmonary accumulation of neu-
trophils and the lung vascular leak of albumin.
These in vivo anti-inflammatory effects of IL-11
were associated with reduced NF-kB activation in
lung, reduced levels of tumor necrosis factor a
(TNF-a) in bronchoalveolar lavage (BAL) fluids,
and diminished up-regulation of lung vascular
ICAM-1. It is interesting that IL-11 did not affect
BAL fluid content of the CXC chemokines, macro-
phage inflammatory protein-2 (MIP-2) and cyto-
kine-inducible neutrophil chemoattractant (CINC);
the presence of IL-11 did not affect these chemo-
kines. However, BAL content of C5a was reduced
by IL-11. These data indicate that IL-11 is a
regulatory cytokine in the lung and that, like other
members of this family, its anti-inflammatory prop-
erties appear to be linked to its suppression of
NF-kB activation, diminished production of TNF-a,
and reduced up-regulation of lung vascular ICAM-1.
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INTRODUCTION
Interleukin-11 (IL-11) was originally identified as a stromal
cell product that stimulated proliferation of IL-6-dependent
plasmacytoma cells [1]. Subsequent studies have demonstrated
that IL-11 has effects similar to IL-6, including megakaryocyte
proliferation [2] and induction of acute phase response proteins
[3]. Functional similarities between IL-6 and IL-11 can be
explained by the fact that signal transduction for both of these
cytokines is mediated through the transmembrane glycoprotein
130 (gp130) receptor component, which is common to both IL-6
and IL-11 receptor complexes [4, 5].
We have previously shown that IL-6 functions as an intrinsic
regulator of lung inflammation induced by intrapulmonary
deposition of IgG immune complexes in rats [6]. The develop-
ment of lung injury in this model is characterized by neutrophil
recruitment and increased vascular permeability in the lung,
these events being linked to production of TNF-a and IL-1b by
activated lung macrophages [7, 8]. Furthermore, activation of
the transcription factor, NF-kB, occurs in a time course similar
to that for the appearance of TNF-a and IL-1b [9]. In this model
of lung injury, exogenous administration of IL-6 caused substan-
tial reductions in bronchoalveolar lavage (BAL) levels of tumor
necrosis factor a (TNF-a), neutrophil accumulation, and lung
vascular permeability [6]. Conversely, blockade of endogenous
IL-6 augments these parameters of lung injury.
Recent studies in vitro have suggested that IL-11 suppresses
proinflammatory cytokine production in activated macrophages
by attenuating NF-kB activation [10]. Other studies have
demonstrated anti-inflammatory effects of IL-11 in models of
chronic inflammation, including trinitrobenzene sulfonic acid
(TNBS)-induced colitis [11], endotoxemia [12], and radiation-
induced thoracic injury [13]. Mice transgenically overexpress-
ing IL-11 in lung develop pulmonary lymphocytic infiltrates,
airway remodeling, and subepithelial fibrosis [14]. In the
current studies we sought to determine the physiological role of
IL-11 during acute lung inflammation induced by IgG immune
complexes. Our data indicate that in this model IL-11 is
up-regulated in lung at both the mRNA and protein levels.
Exogenous administration of IL-11 suppresses IgG immune
complex-induced neutrophil accumulation and lung vascular
permeability. IL-11 also suppresses lung NF-kB activation in
association with reduced BAL levels of TNF-a and decreased
pulmonary vascular expression of ICAM-1. At the same time,
C5a levels in the lung are reduced but BAL levels of the CXC
chemokines, MIP-2 and CINC, are unaffected. These data
indicate that IL-11 has the ability to regulate the acute lung
inflammatory response.
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METHODS
Reagents
Human recombinant IL-11 and mouse monoclonal IgG1 anti-human IL-11
(clone 11h3/19.6.1) were gifts from Genetics Institute, Inc. (Cambridge, MA).
Mouse monoclonal IgG1 anti-rat ICAM-1 (clone 1A29) was purchased from
PharMingen, Inc. (San Diego, CA). Irrelevant mouse IgG1 (clone MOPC-21)
was purchased from ICN Biomedicals, Inc. (Costa Mesa, CA). All other
reagents, unless otherwise indicated, were purchased from Sigma (St. Louis,
MO).
IgG immune complex-induced alveolitis
Pathogen-free male Long-Evans rats (275–300 g; Harlan Sprague-Dawley,
Indianapolis, IN) were anesthetized with ketamine HCl (150 mg/kg, intraperito-
neally). Rats received intratracheal administration of 1.5 mg antibody to bovine
serum albumin (anti-BSA; ICN Biomedicals, Inc.) in a volume of 0.3 mL
phosphate-buffered saline (PBS). Negative control rats received intratracheal
administration of PBS, pH 7.4. Immediately thereafter, 10 mg BSA (,1 ng
endotoxin/mg) in 0.5 mL PBS was injected intravenously. For analysis of
pulmonary vascular permeability, trace amounts of 125I-labeled BSA were
injected intravenously. Four hours after IgG immune complex deposition, rats
were exsanguinated, the pulmonary circulation was flushed with 10 mL PBS by
pulmonary artery injection, and the lungs surgically removed. The extent of
lung injury was quantified by calculating the lung permeability index [dividing
the amount of radioactivity (125I-labeled BSA) in the perfused lungs by the
amount of radioactivity in 1.0 mL of blood obtained from the inferior vena cava
at the time of death]. For measurement of lung NF-kB activation, lungs were
surgically dissected and immediately frozen in liquid nitrogen.
Reverse transcription-polymerase chain reaction
(RT-PCR)
Total RNA from whole lung tissue was extracted using a guanidinium-
isothiocyanate method as described previously [15]. Total RNA (20 µg) was
reverse transcribed to cDNA. The cDNA products were amplified by PCR (35
cycles; 1 min each at 95, 55, and 72°C). The 58 primer (58-ATGAACTGTGTTT-
GTCGCCTG-38) and 38 primer (58-GTTGTTAAAGACTCGACTGTG-38) were
complementary to 58 and 38 regions of the open reading frame of the human
IL-11 sequence. PCR products were sequenced for verification. RT-PCR of the
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA was performed
(58 primer, 58-TCACCATCTTCCAG GAGC-38; 38 primer, 58-CTGCTTCAC-
CACCTTCTTGA-38) under the same conditions described above to confirm
equal loading of RNA. PCR products were electrophoresed in a 1% agarose gel
and stained with ethidium bromide. Photographs of PCR products were
digitized and analyzed using image analysis software (Adobe Systems, San Jose,
CA).
Western blot analysis
BAL fluids were concentrated approximately 100-fold and 40 µL were
separated in a denaturing 15% polyacrylamide gel and transferred to a
0.1-µm-pore nitrocellulose membrane. Nonspecific binding sites were blocked
with TBS (40 mM Tris, pH 7.6, 300 mM NaCl) containing 5% nonfat dry milk
for 12 h at 4°C. Membranes were then incubated in monoclonal mouse IgG
anti-IL-11 (2 µg/mL) in TBS with 0.1% Tween 20 (TBST). After three washes in
TBST, membranes were incubated in a 1:10,000 dilution of horseradish
peroxidase-conjugated sheep anti-mouse IgG (Amersham, Arlington Heights,
IL). Immunoreactive proteins were detected by enhanced chemiluminescence.
NF-kB activation by electrophoretic mobility shift
assay (EMSA)
Nuclear extracts of whole lung tissues were prepared by the method of
Deryckere and Gannon [16]. Protein concentrations were determined by
bicinchoninic acid assay with trichloroacetic acid precipitation using BSA as a
reference standard (Pierce, Rockford, IL). Double-stranded NF-kB consensus
oligonucleotide (58-AGTGAGGGGACTTTCCCAGGC-38; Promega, Madison,
WI) was end-labeled with [g-32P]ATP (3,000 Ci/mmol at 10 mCi/mL, Amer-
sham). Binding reactions containing equal amounts of protein (10 µg) and 35
fmol (,50,000 cpm, Cherenkov counting) of oligonucleotide were performed
for 30 min in binding buffer (4% glycerol, 1 mM MgCl2, 0.5 mM EDTA, pH 8.0,
0.5 mM dithiothreitol, 50 mM NaCl, 10 mM Tris, pH 7.6, 50 µg/mL poly
(dI-dC); Pharmacia, Piscataway, NJ). Reaction volumes were held constant at
15 µL. Reaction products were separated in a 4% polyacrylamide gel and
analyzed by autoradiography. NF-kB activation was quantitated from digitized
autoradiography films using image analysis software (Adobe Systems).
Lung vascular expression of ICAM-1
Rats were injected intravenously with 1.5 µCi of 125I-labeled anti-ICAM-1 3.75
h after induction of lung injury. The specific activity of the anti-ICAM-1 was
11.3 µCi/µg. Fifteen minutes later (4 h after induction of lung injury), rats were
killed and the lung vasculature was flushed with 10 mL PBS. Lung vascular
ICAM-1 expression (binding index) was calculated by dividing the amount of
radioactivity (125I-labeled antibody) in perfused lungs by the amount of
radioactivity in 1.0 mL of blood. To control for nonspecific binding and
potential accumulation of anti-ICAM-1 antibody in lung parenchyma due to
injury, 1.5 µCi of 125I-labeled nonspecific mouse IgG1 were administered in a
separate set of rats undergoing IgG immune complex lung injury. The specific
activity of the irrelevant IgG antibody was 13.0 µCi/µg. This technique has been
described in detail elsewhere [17].
Lung myeloperoxidase (MPO) content
Whole-lung MPO activity was quantitated as described previously [18]. Briefly,
whole lungs homogenates were diluted in 50 mM potassium phosphate buffer
containing 0.5% hexadecyltrimethylammonium bromide, pH 6.0. After sonica-
tion and two freeze-thaw cycles, samples were centrifuged at 4000 g for 30 min.
The supernatants were reacted with H2O2 (0.3 mM) in the presence of
tetramethylbenzidine (1.6 mM). MPO activity was assessed by measuring the
change in absorbance at 655 nm.
BAL fluid neutrophil and cytokine content
BAL fluids were collected by instilling and withdrawing 5 mL of sterile PBS
three times from the lungs via an intratracheal cannula. Cellular contents were
recovered by centrifugation and neutrophils were counted by microcytometry.
BAL content of TNF-a was measured using a standard WEHI cell cytotoxicity
assay as previously reported [19]. Measurement of CINC, macrophage inflam-
matory protein-2 (MIP-2), and C5a in BAL fluids was by enzyme-linked
immunosorbent assay (ELISA) as described elsewhere [20, 21].
Statistical analyses
All values are expressed as means 6 SEM. Data were analyzed with a one-way
analysis of variance and individual group means were then compared with a
Student-Newman-Keuls test. Differences were considered significant when
P , 0.05. For calculations of percent change, negative control values were
subtracted from positive control and treatment group values.
RESULTS
Pulmonary expression of IL-11 during IgG
immune complex alveolitis
Expression of IL-11 mRNA in lung extracts from rats undergo-
ing IgG immune complex-induced lung injury was determined
by RT-PCR. IL-11 mRNA was constitutively expressed at very
low levels in lung, the RT-PCR product being present at the
initiation of lung injury (time 0; Fig. 1). IL-11 mRNA
expression increased 30 min after intrapulmonary deposition of
IgG immune complexes, reaching a maximal level after 1 h,
declining at 2 h, and returning to baseline 4 h after initiation of
injury. In accordance with IL-11 mRNA, IL-11 protein was
constitutively expressed at low levels in lung before initiation of
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the lung inflammatory reaction. Western blot analysis of
concentrated BAL fluids demonstrated barely detectable levels
of IL-11 protein at the initiation of lung injury (time 0; Fig. 2).
Expression of IL-11 protein was markedly increased 1 h after
IgG immune complex deposition and further increases were
detected at 2 and 4 h.
Effects of exogenous IL-11 on IgG immune
complex-induced neutrophil accumulation and
lung injury
Experiments were designed to assess the effects of exogenously
administered recombinant human IL-11 on lung vascular
permeability and lung neutrophil recruitment in the IgG
immune complex model of lung injury. The extent of lung injury
was determined by extravascular leakage of albumin. Intrapul-
monary deposition of IgG immune complexes caused a three-
fold increase in the lung permeability index (Fig. 3A).
Intratracheal administration of IL-11 (administered with the
anti-BSA) caused a dose-dependent reduction in the lung
permeability index. In the presence of 10, 30, or 60 µg IL-11,
the permeability index was reduced 29% (P, NS), 43% (P, NS)
and 66% (P , 0.05), respectively. To assess whether the
protective effects of IL-11 were related to reduced pulmonary
recruitment of neutrophils, lung MPO content and the number
of neutrophils in BAL fluids were determined. Treatment with
IL-11 caused dose-dependent decreases in lung MPO content
(Fig. 3B). Intratracheal administration of 10, 30, or 60 µg IL-11
reduced lung MPO content by 12% (P, NS), 58% (P , 0.05),
and 67% (P , 0.05), respectively. Similarly, 60 µg IL-11
decreased the number of neutrophils present in BAL fluids
from 65.9 6 3.5 3 103 cells/mL in positive controls to 22.0 6
3.6 3 103 cells/mL, a reduction of 67% (P , 0.05).
Fig. 1. Expression of rat IL-11 mRNA during IgG immune complex alveolitis.
Lung RNA extracts were analyzed by RT-PCR (A) and ethidium bromide-
stained PCR products were digitized using image analysis (B). Equal loading of
RNA was confirmed by RT-PCR of the housekeeping gene, GAPDH. Results
are representative of three independent experiments.
Fig. 2. BAL fluid content of IL-11 protein during IgG immune complex
alveolitis. BAL fluids were concentrated (100-fold) and 40 µL were analyzed by
Western blot. Recombinant human IL-11 was used as a reference standard (std)
in the extreme left lane. Results are representative of two independent
experiments.
Fig. 3. Effects of IL-11 on IgG immune complex-induced lung vascular
permeability (A) and lung neutrophil accumulation (B). Permeability index
(n 5 5–9) and lung MPO content (n 5 3–7) were assessed 4 h after
intratracheal administration of 1.5 mg anti-BSA followed by intravenous
infusion of 10 mg BSA. IL-11 was administered intratracheally with the IgG
anti-BSA. Values represent mean 6 SEM.
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Effects of IL-11 on lung NF-kB activation
In the IgG immune complex model, development of lung
inflammatory injury is associated with a progressive increase in
lung NF-kB activation as defined by nuclear translocation of
NF-kB [9]. In vitro studies have shown that IL-11 suppresses
NF-kB activation in macrophages [10]. Therefore, to investi-
gate whether the protective effects of IL-11 might be related to
inhibition of pulmonary NF-kB activation, nuclear extracts
from whole lungs harvested 4 h after IgG immune complex
deposition were analyzed by EMSA. Little NF-kB was present
in lung nuclei from rats treated intratracheally with PBS
(negative control, Fig. 4A). As expected, intrapulmonary
deposition of IgG immune complexes caused a significant
increase in nuclear translocation of NF-kB. Image analysis of
digitized EMSA blots demonstrated that, in the presence of 10,
30, or 60 µg IL-11, NF-kB activation was reduced by 12 (P,
NS), 28 (P, NS), and 34% (P , 0.05), respectively (Fig. 4B).
Effects of IL-11 on BAL Levels of TNF-a and
lung vascular expression of ICAM-1
NF-kB is known to control, at least in part, the gene expression
of both TNF-a and ICAM-1 [22, 23]. Furthermore, TNF-a
regulates lung vascular expression of ICAM-1 [17], which is
required for pulmonary neutrophil recruitment [24]. Therefore,
we performed experiments to determine whether exogenously
administered IL-11 affected BAL levels of TNF-a and lung
vascular expression of ICAM-1. BAL TNF-a content was
determined by the WEHI bioassay. The lung inflammatory
response led to significantly increased BAL levels of TNF-a
(from ,20 ng/mL to .600 ng/mL, Fig. 5A). In the presence of
60 µg IL-11 BAL levels of TNF-a were reduced by 70% (P ,
0.05). Pulmonary expression of ICAM-1 was determined by the
lung binding index of 125I-anti-ICAM-1. As expected, intrapul-
Fig. 4. Effects of exogenously administered recombinant human IL-11 on IgG
immune complex-induced lung NF-kB activation. (A) NF-kB activation in
whole lung tissues harvested 4 h after intratracheal administration of PBS or 1.5
mg anti-BSA (IgG-IC) followed by intravenous infusion of 10 mg BSA. IL-11
was administered intratracheally with the IgG anti-BSA. (B) Quantitation of
EMSA blots by image analysis. Values represent mean 6 SEM, with n 5 4–5 for
each group.
Fig. 5. Effects of IL-11 on IgG immune complex-induced BAL TNF-a and
lung vascular ICAM-1 expression. (A) BAL fluids harvested 4 h after
intratracheal administration of PBS or 1.5 mg anti-BSA (IgG-IC) followed by
intravenous infusion of 10 mg BSA were analyzed by the WEHI assay for
TNF-a bioactivity. (B) lung vascular ICAM-1 expression was determined 4 h
after IgG-IC deposition using vascular fixation of 125I-anti-rat ICAM-1. Values
represent mean 6 SEM, with n 5 5–6 for each group.
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monary deposition of IgG immune complexes caused a signifi-
cant increase in the ICAM-1 binding index (Fig. 5B). In the
presence of 60 µg IL-11, the binding index for ICAM-1 was
reduced by 48% (P , 0.05). The increase in binding index for
the anti-ICAM-1 could not be attributed to nonspecific binding
or sequestration due to lung injury because the binding index
for the irrelevant IgG control antibody was less than 0.10 in
both inflamed and non-inflamed lungs (data not shown).
Effects of IL-11 on neutrophil chemoattractants in
BAL fluids
To determine the effects of IL-11 on chemotactic mediators
known to be involved in pulmonary neutrophil recruitment in
this inflammatory model, we assessed the effects of 60 µg IL-11
on IgG immune complex-induced BAL content of the CXC
chemokines, MIP-2 and CINC, and the complement activation
product, C5a. BAL fluids were obtained 4 h after the initiation
of the lung inflammatory reaction. MIP-2, CINC, and C5a were
evaluated by ELISA. Intrapulmonary deposition of IgG immune
complexes caused significant increases in BAL levels of MIP-2,
CINC, and C5a, with a 38-fold increase of MIP-2, a nearly
300-fold increase of CINC, and a 7-fold increase of C5a (Table
1). In the presence of 60 µg IL-11, the BAL levels of MIP-2 and
CINC were not significantly altered but there was a 29%
decrease (P , 0.05) in BAL levels of C5a (Table 1).
DISCUSSION
There is mounting evidence that IL-11 plays an important
regulatory role in the inflammatory response. Previous studies
have suggested that exogenously administered IL-11 reduced
tissue injury in a number of experimental models of chronic
inflammatory disease, including TNBS-induced colitis, endotox-
emia, and radiation-induced thoracic injury [11–13]. In the last
example, the protective effects of IL-11 correlated with reduced
intrapulmonary production of TNF-a [13]. In the current study,
we investigated whether IL-11 could suppress the acute
inflammatory response in lung and if so, by what mechanism.
Intrapulmonary deposition of IgG immune complexes causes
distal airway activation of the complement system and genera-
tion of the complement activation product, C5a. Blockade of
intrapulmonary C5a with antibody reduced lung production of
TNF-a, diminished up-regulation of vascular ICAM-1, and
reduced neutrophil accumulation and the intensity of lung
injury [25]. In this lung inflammatory model, enhanced produc-
tion of TNF-a and IL-1b by activated macrophages is required
for up-regulation of the adhesion molecules, ICAM-1 and
E-selectin, on pulmonary vascular endothelial cells [17, 26].
Interactions of these vascular adhesion molecules with their
respective ligands on blood neutrophils causes leukocyte
adhesion to the endothelium and CXC chemokine-dependent
recruitment of neutrophils into the alveolar compartment. The
ensuing lung injury is mediated by oxidants and proteases
released by neutrophils and from activated lung macrophages.
Injury is characterized by increased vascular permeability and
alveolar hemorrhage [27]. In this study we found that IL-11 was
up-regulated at the mRNA and protein levels during the lung
inflammatory response. Exogenously administered IL-11 attenu-
ated intrapulmonary activation of NF-kB, reduced lung produc-
tion of TNF-a, and diminished pulmonary vascular expression
of ICAM-1. In the presence of IL-11, intrapulmonary genera-
tion of C5a was reduced by an unknown mechanism. These
effects were accompanied by reduced neutrophil accumulation
and lung injury. The data suggest that IL-11 may function as an
intrinsic regulator of the acute inflammatory response in lung.
The lack of availability of a blocking antibody to rat IL-11
precludes the definitive in vivo experiments to settle this
question.
Exogenous administration of IL-11 attenuated activation of
NF-kB in lung. These findings are consistent with in vitro
studies which showed that IL-11 inhibited LPS-induced NF-kB
activation in macrophages [10]. It is interesting that IL-11
reduced IgG immune complex-induced lung NF-kB activation
by 34%, whereas TNF-a production was reduced by 70%.
Previous studies in this model have demonstrated that exog-
enous administration of the anti-inflammatory cytokines, IL-10
and IL-13, almost completely inhibits lung NF-kB activation
and suppresses TNF-a production by more than 95% [9, 28].
Despite the fact that IL-10 and IL-13 signal through receptor
pathways different from the pathway for IL-11, it would seem
that the reduction in lung NF-kB activation caused by IL-11
may only partially explain inhibition of TNF-a in BAL fluids. If
it is predominantly macrophages that are the target for the
suppressive effects of IL-11, nuclear extracts from whole lungs
may underestimate the suppression of NF-kB in lung macro-
phages.
In the lung inflammatory response, intrapulmonary genera-
tion of C5a is known to be required for the full production of
TNF-a [25]. The present report provides evidence that IL-11
reduces the generation of C5a during IgG immune complex
alveolitis. How IL-11 might affect the intrapulmonary genera-
tion of C5a is unclear. IL-11 is known to stimulate the
production of the tissue inhibitor of metalloproteinase-1 [29]. If
a non-complement-related C5-cleaving enzyme in lung, such as
a matrix metalloproteinase, is responsible for production of at
least some C5a, it is possible that IL-11 induces up-regulation
of natural inhibitors for such an enzyme (e.g., by up-regulating
tissue inhibitor of metalloproteinase-2), thereby reducing the
amount of C5a generated. Until the nature of the C5-cleaving
enzyme in lung is known, the possible mechanism of the
suppressive effects of IL-11 on C5a generation remains specu-
lative. Accordingly, the effects of IL-11 in vivo suggest that
IL-11 may reduce lung production of TNF-a by two separate
mechanisms involving NF-kB and C5a. These mechanisms may
TABLE 1. Effects of IL-11 on BAL Levels of MIP-2,
CINC, and C5a
Group MIP-2 (ng/mL) CINC (ng/mL) C5a (ng/mL)
PBS 15.1 6 8.6 5.6 6 6.3 0.35 6 0.05
IgG-IC 572.6 6 63.9* 1589.8 6 137.9* 2.42 6 0.13*
IgG-IC 1 IL-11 503.6 6 31.7* 1478.6 6 78.7* 1.82 6 0.14†
Values represent mean 6 SEM, with n 5 5 for each group. Human
recombinant IL-11 was used at a dose of 60 µg, administered intratracheally.
IC, immune complexes. * P , 0.05 compared to PBS group; † P , 0.05
compared to IgG-IC group.
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also be relevant to the regulation of pulmonary vascular
expression of ICAM-1. Both NF-kB and C5a are known to
regulate, by direct or indirect mechanisms, vascular endothe-
lial cell expression of ICAM-1. NF-kB directly controls gene
expression of ICAM-1 as well as the ICAM-1 inducer, TNF-a
[22, 23], whereas C5a regulates ICAM-1 expression through
effects on TNF-a production [25]. It seems likely that IL-11-
induced inhibition of pulmonary neutrophil recruitment and
ensuing lung injury can be attributed to reductions in intrapul-
monary C5a, TNF-a, and pulmonary vascular expression of
ICAM-1 because IL-11 had no effect on the CXC chemokines,
MIP-2 and CINC. As indicated above, both of these CXC
chemokines are known to be required for full recruitment of
neutrophils in this model of lung injury. It remains to be
determined how the presence of IL-11 affects intrapulmonary
generation of C5a. Thus, the regulatory effects of IL-11 on the
lung inflammatory response are restricted in scope.
Why transgenic expression of IL-11 in murine lung leads to
accumulation of lymphocytes and increased airway resistance
is not clear [14]. However, the predominantly B cell phenotype
of the lung lymphocytic infiltrates in IL-11 transgenic mice
suggests that the B cell stimulatory activity of IL-11 may
contribute to this outcome [30]. The mechanisms for the fibrotic
airway obstruction in IL-11 transgenic mice remains to be
determined. Whether intermittent expression of IL-11 in lung
would yield an outcome different from persistent expression of
IL-11 in transgenic mice is unclear.
This report further extends our current knowledge concern-
ing the biology of IL-11. We demonstrate the anti-inflammatory
effects of IL-11 and have identified the protective mechanisms
of IL-11 in lung after intrapulmonary deposition of IgG immune
complexes. The data demonstrate that IL-11 functions as a
down-regulator of the acute inflammatory response. Further-
more, IL-11 is up-regulated at the mRNA and protein levels
during the course of inflammation. These findings are similar to
those described previously for IL-6, suggesting that IL-11 may
have overlapping functions with IL-6 in the regulation of acute
lung inflammation. The dose responses of IL-6 and IL-11 are
similar and are a log dose greater than for the effects of IL-10
and IL-13 [28]. All of these interleukins appear to achieve
these effects via a common mechanism: suppression of NF-kB
activation and related TNF-a production in lung, leading to
reduced expression of lung vascular ICAM-1. In turn, neutro-
phil recruitment is reduced, as is the development of lung
injury. At present, IL-11 can be added to the list of regulatory
cytokines, which also include IL-4, IL-6, IL-10, IL-12, and
IL-13.
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